SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support ...
"Therapy for small, node-negative, HER2-positive breast cancer can be challenging due to the risk of overtreatment. Our study can help assess outcomes of patients according to specific tumor sizes and ...
HER2-positive breast cancer, once associated with poor outcomes, now sees improved prognosis due to targeted therapies like Herceptin. Combination therapies and neoadjuvant treatments have enhanced ...
Enhertu plus Perjeta showed superior PFS compared to THP in HER2-positive advanced/metastatic breast cancer, irrespective of prior treatment, hormone receptor status, or PIK3CA mutations. Enhertu plus ...
In patients with metastatic breast cancer (BC), the prevalence of brain metastases increased with each treatment line, rising the most among patients with hormone receptor (HR)–negative, human ...
Please provide your email address to receive an email when new articles are posted on . The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)–positive advanced or metastatic breast cancer. The efficacy and safety of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results